Aleksandra Sadowska | Oliver Nic Hausmann
Karin Wuertz-Kozak

Inflammaging in the intervertebral disc

Suggested citation referring to the original publication:
Clinical and Translational Neuroscience January-June 2018 (2018)
DOI http://dx.doi.org/10.1177/2514183X18761146
ISSN (online) 2514-183X

Postprint archived at the Institutional Repository of the Potsdam University in:
Postprints der Universität Potsdam
Humanwissenschaftliche Reihe ; 519
ISSN 1866-8364
http://nbn-resolving.de/urn:nbn:de:kobv:517-opus4-414081
DOI https://doi.org/10.25932/publishup-41408
Inflammaging in the intervertebral disc

Aleksandra Sadowska1, Oliver Nic Hausmann2, and Karin Wuertz-Kozak1,3,4,5

Abstract
Degeneration of the intervertebral disc – triggered by ageing, mechanical stress, traumatic injury, infection, inflammation and other factors – has a significant role in the development of low back pain. Back pain not only has a high prevalence, but also a major socio-economic impact. With the ageing population, its occurrence and costs are expected to grow even more in the future. Disc degeneration is characterized by matrix breakdown, loss in proteoglycans and thus water content, disc height loss and an increase in inflammatory molecules. The accumulation of cytokines, such as interleukin (IL)-1β, IL-8 or tumor necrosis factor (TNF)-α, together with age-related immune deficiency, leads to the so-called inflammaging – low-grade, chronic inflammation with a crucial role in pain development. Despite the relevance of these molecular processes, current therapies target symptoms, but not underlying causes. This review describes the biological and biomechanical changes that occur in a degenerated disc, discusses the connection between disc degeneration and inflammaging, highlights factors that enhance the inflammatory processes in disc pathologies and suggests future research avenues.

Keywords
Intervertebral disc, chronic inflammation, inflammaging, senescence, mechanical loading, matrix fragmentation, obesity, Propionibacterium acnes

The concept of inflammaging
During the course of life, humans are exposed to numerous internal and external damaging agents, including products of metabolic stress, UV light or pathogens. The body can counterbalance the detrimental effects that these stressors exert by various mechanisms (DNA repair, cell apoptosis/autophagy, etc.), at least to a certain degree.1 Induction of immune and inflammatory processes are also a part of the body’s toolbox to shield itself from these types of dangers, but to ensure healthy ageing, later neutralization of these inflammatory processes is required. However, there are cumulative data indicating a decrease in the counteraction capacity with increasing age.1 Consequently, pathology-associated ageing that is linked to an imbalance between inflammatory and anti-inflammatory networks occurs. This imbalance is further promoted by age-related immune deficiency termed immunosenescence, which entails a reduced capability of the body to effectively combat stressors.2 The resulting low-grade, chronic inflammation was termed inflammaging by Franceschi et al.3 Since then, inflammaging (also known as inflamm-ageing4) was found to induce endocrine, metabolic and nutritional changes that likewise promote pro-inflammatory conditions.5 Importantly, recent research highlighted that inflammaging is based on a complex relationship between pro- and anti-inflammatory markers, including the activation of counter-regulatory mechanism.6 Inflammaging has been described as an important contributor to numerous age-related diseases, including osteoarthritis, Alzheimer’s disease, atherosclerosis, heart disease or type II diabetes.4 In

1 ETH Zurich, Zurich, Switzerland
2 Klinik St. Anna-Hirslanden, Neuro- and Spine Center, Lucerne, Switzerland
3 Department of Health Sciences, University of Potsdam, Potsdam, Germany
4 Schön Klinik München Harlaching, Spine Center, Munich, Germany
5 Academic Teaching Hospital and Spine Research Institute, Paracelsus Private Medical University Salzburg, Salzburg, Austria

Corresponding author:
Karin Wuertz-Kozak, ETH Zurich, Hoenggerbergring 64, HPP-012, Zurich, 8093, Switzerland.
Email: kwuertz@ethz.ch
the musculoskeletal system, age-related changes include loss of bone mass, as well as degradation of cartilage and intervertebral disc (IVD) tissues. As the term inflamming has recently also emerged in the context of disc pathologies, the subsequent chapters will provide an overview of the current state of the art.

Ageing and degeneration of the IVD

Degeneration of the IVD is a major contributor to low back pain (LBP). Due to the lifetime prevalence of 84%, LBP – and thus also disc degeneration – has a major socio-economic impact. In fact, the financial burden related to LBP is approximately 2% of the national gross domestic product in various countries.

IVD degeneration is an age-related process, with an early onset. Ageing IVDs are characterized by a shift from anabolism towards catabolism, with a consequent matrix breakdown, loss of hydration in the nucleus pulposus (NP) and reduction in disc height. These changes not only result in altered biomechanics but also in neovascularization and neoinnervation, at least in the annulus fibrosus (AF). With ageing and the loss of tissue homeostasis, cells are exposed to damaging factors (such as damaged matrix products, toxins or oxidative stress), leading to increased cell death and senescence.

The prevalence of IVD degeneration is vast. A recent cross-sectional population study with 1043 volunteers showed that 40% of individuals under 30 years of age had IVD degeneration, with an increase to over 90% in the 50- to 55-year-old group. Due to ongoing ageing of the population, the number of those with IVD degeneration – and thus the associated socio-economic impact – will even further increase in the future. However, it has to be noted that only a subpopulation develops painful disc degeneration, whereas it is asymptomatic in approximately two-thirds of the population. As described in more detail in the later sections, inflammation and inflamming contribute to disc-related LBP.

Inflammation and degenerative disc disease

Inflammation has been described as the major pathological contributor to the development of painful disc degeneration, also termed degenerative disc disease (DDD). While local inflammation arising within the IVD tissue has been extensively studied over the past decade, first evidence also points to the role of systemic inflammation in DDD. Table 1 summarizes the pro-inflammatory molecules that are involved in the development of DDD.

Systemic inflammation

With technical advancements in the cost-effective analysis of proteins, clinicians and researchers have become increasingly interested in the identification of biomarkers in the biological fluids of patients, predominantly blood.
Biomarkers can be of tremendous value not only in early
detection of diseases and prognosis, but also in manage-
ment and monitoring.

Studies investigating serum samples demonstrated an age-
dependent increase in numerous inflammatory cytokines,
including interleukin (IL)-6 and tumor necrosis factor-α
(TNF-α), supporting the notion of age-associated chronic,
low-grade inflammation and hence inflammaging.20,21 Inter-
estingly, a meta-analysis of eight studies, including 263 sub-
jects with IVD degeneration (bulging, protrusion or sequestra-
tion) and 129 healthy controls, demonstrated an
association between IL-6 serum levels and the occurrence
of IVD degeneration, with higher levels in those affected.22

Recent work by Weber et al. not only confirmed that serum
IL-6 correlated with age but also highlighted that levels were
significantly higher in subjects with LBP arising from disc
herniation (DH), DDD or spinal stenosis, compared with non-
affected controls.23 As participants were controlled for age
during recruitment, these findings point towards a general
presence of inflammaging, but with disease-specific altera-
tions in the cytokine expression patterns. Furthermore, higher
IL-6 serum levels were reported as an indicator of inferior
recovery in patients with lumbar radicular pain due to lumbar
DH over the course of 1 year, as demonstrated by the Oswes-
try Disability Index and visual analogue scale.24 Aside from
IL-6, IL-8 has also been suggested as a potential biomarker in
DH and the level of associated pain, but possibly also in DDD
without the occurrence of IVD protrusion.25,26

In summary, these results indicate that systemic inflam-
mation not only represents a link between ageing and IVD
pathology, but also disc-related LBP.

Local inflammation

Past research has provided ample evidence for the expres-
sion of inflammatory mediators in the IVD, including IL-
1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-17, TNF-α,
prostaglandin E2 (PGE2) and interferon-γ (IFN-γ), partially
with an age- and degeneration-dependent expression profile.29–31 Importantly, invading cells of the immune
system, for example, in case of herniation, can produce pro-inflammatory cytokines. IVD cells themselves are also a
source of pro-inflammatory cytokines, with some differ-
ences between NP and AF cells, for example, with regard to
IL-1α, IL-1β, IL-6, IL-17 and TNF-α.8,31

Several of these inflammatory mediators are major
pathological markers, with higher levels in “diseased”
IVDs. Higher levels of TNF-α and IL-8 were measured
in DDD samples compared to DH samples and this likely
contributes to more severe back pain commonly observed
in DDD patients.33 On the other hand, DH samples – which
are characterized by enhanced macrophage infiltration and
rare lymphocyte infiltration – possess higher levels of IL-4,
IL-6, IL-12 and IFN-γ than DDD samples.32

The presence of these inflammatory mediators not only
aggravates IVD degeneration, for example, by inducing the

| Table 1. Pro-inflammatory cytokines involved in DDD. For more information, please refer to the cited literature. |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| IL-1α | IL-1β | IL-2  | IL-4  | IL-6  | IL-8  | TNF-α | PGE2  | IFN-γ |
| Systemically increased | 2021.2323 | 25 | 32  | 32  | 32  | 38  | 8  | 27/28/33/36/41 |
| Locally increased | 27/28/33 | 27/28/33/36 | 27/28/33/36/38 | 27/28/33/36 | 27/28/33/36 | 27/28/33/36 | 27/28/33/36 | 27/28/33/36 | 27/28/33/36 |

DDD: degenerative disc disease; IL: interleukin; TNF: tumor necrosis factor; PGE: prostaglandin; IFN: interferon.
expression of matrix degrading enzymes, by enhancing cellular senescence, as well as by inhibiting extracellular matrix (ECM) synthesis, but also plays a crucial role in pain development. In fact, there is clear evidence that a variety of pro-inflammatory cytokines are upregulated in patients with higher pain sensation (such as IL-1β, IL-6, IL-8, IL-10, TNF-α, IFN-γ) – albeit with differences between studies likely associated with patient selection and consequent dissimilarities in pathology inclusion criteria.

The mechanisms of cytokine-induced pain sensation are complex. During DH, pain sensation can be due to mechanochemical irritation of spinal nerves caused by the inflammatory nature of the extruded NP material (radiculopathy) and/or nerve infiltration into the compromised disc (nociception). In cases of DDD, LBP develops through newly inflammatory nature of the extruded NP material (radiculopathy) and/or nerve infiltration into the compromised disc (nociception). In cases of DDD, LBP develops through newly induced premature senescence, and both can be present in the IVD cells. Both types of senescence share similar phenotypic features, including a shift towards an immunogenic phenotype. This phenotype is generally known as senescence-associated secretory phenotype (SASP).

Two general forms of senescence exist, typically termed as (telomere-dependent) replicative senescence and stress-induced premature senescence, and both can be present in the IVD cells. Both types of senescence share similar phenotypic features, including a shift towards an immunogenic phenotype. This phenotype is generally known as senescence-associated secretory phenotype (SASP) and is characterized by a pro-inflammatory secretome (the collection of proteins secreted by a cell), with enhanced expression of IL-6, IL-8 and IFN-γ in IVD cells. Furthermore, senescent cells are responsible for enhanced catabolism and ECM degradation through stimulation of matrix metalloproteinases (MMP) -1, -2, -3, -9, and -13. Therefore, senescence is likely an important contributor to premature disc ageing and inflammaging (Figure 1).

**Mechanical loading**

The IVD is a mechanically complex tissue, in which hydrostatic pressure/compression and osmotic stresses predominate in the NP and tensile and shear stresses preside in AF. IVD cells have been shown to respond to mechanical stresses in a dose-, frequency-, duration- and zone-specific manner. Moderate physiological levels of stress produce anabolic responses, whereas hyper-physiological stresses not only bias towards catabolism and reduced viability, but also induce inflammation.

Importantly, ageing and consequent degeneration alter the load distribution in IVDs and result in higher compressive axial and tensile radial strains. Areas of peak stresses hence exist within degenerated IVDs. Cells located in these regions will experience disproportionately high loads during normal physiological activities, hence responding with catabolism and inflammation rather than anabolism (Figure 1). In fact, previous research has demonstrated that cellular responses to physical stress are graded by the degree of tissue degeneration. Transient receptor potential (TRP) channels, a family of multimodal cation channels, may represent a molecular link between mechanical loading and inflammation in the IVD. TRP channels, which have been described to play a crucial role not only in mechanosensing, but also in transmission of inflammation and pain, have recently been detected in the IVD. The mechanism of locally altered load distribution, together with potentially altered mechanotransduction mechanisms (e.g. vial-altered TRP channel expression with ageing and degeneration), helps to rationalize why mechanical loading originating from normal daily activities may result in low-grade inflammation in ageing IVDs.

**Matrix degradation**

Age-associated degeneration of the IVD is characterized by degradation of the ECM, leading to a decrease not only in total proteoglycan and collagen content, but also in altered expression and synthesis of other matrix components. Specific enzymes, for example, reactive oxygen species, can induce fragmentation of these ECM proteins. A number of these fragments have been described to be biologically active and some possess inflammatory properties (Figure 1). In fact, fragments of hyaluronic acid were already shown to induce catabolic and inflammatory responses in IVD cells.

Aside from hyaluronic acid fragments, additional matrix cleavage products occurring during ageing and degeneration of the IVD may contribute to IVD inflammaging, albeit likely in a size-specific manner. Fragmentation of the small, leucine-rich proteoglycan biglycan takes place in pathological human IVDs and these
Bacterial infection

Propionibacterium acnes (P. acnes) infection is one of the hypothesized causes of the development of chronic, low-grade IVD infection and Modic changes. Due to IVD ageing and altered IVD biomechanics, clefts and tears occurring in the outer layer of the AF promote neovascularization and allow for easier bacterial invasion. Importantly, this new microenvironment can enhance the growth of anaerobic bacteria.

Previously, bacterial infection with, for example, P. acnes was believed to arise from epidural injections and contaminations during surgeries or tissue collection. However, recent studies were able to demonstrate that an infection with P. acnes is likely independent of these factors.

Although P. acnes infection is associated with chronic inflammation in IVDs (Figure 1), with stimulation of various pro-inflammatory cytokines (e.g. IL-8, macrophage inflammatory protein (MIP)-1α, TNF-α), the exact mechanism of inflammation induction remains unknown. However, recent evidences point towards activation of Toll-like receptors (TLR) 2 and 4, and subsequent induction of the NF-kB pathway.

Obesity

Obesity is linked not only to a large number of comorbidities, including a significant association with the incidence of type II diabetes, various types of cancer, cardiovascular diseases, asthma or osteoarthritis, but also with the development of disc degeneration and chronic back pain. A recent meta-analysis calculated that the risk of LBP increased by approximately two fold in obese patients, but with a relatively weak statistical association (odds ratio 1.8). Interestingly, when patient selection criteria were tightened, focusing solely on morbidly obese people (body mass index ≥40), the prevalence of LBP was significantly higher in the obese group compared to a control group with normal weight, demonstrating that relevant weight thresholds may exist. The underlying pathophysiological mechanism leading to disc degeneration, DDD and LBP in obese patients is believed to be three fold.

Firstly, increased mechanical loading originating from the excessive body weight in obese patients is thought to contribute to reduced disc height (i.e. disc space narrowing), increased severity of disc degeneration and a higher number of degenerated levels in the lumbar spine. As described above, alterations in the loading patterns, especially in case of coexisting degeneration of the IVD, can lead to inflammatory responses and may play a part in the observed inter-relationship between obesity, disc height and recent pain.

Secondly, overweight or obese patients may have a higher prevalence of LBP due to enhanced systemic expression of fat-derived inflammatory mediators. Adipocytes can produce cytokines, especially with ageing, when they undergo a phenotypic shift towards a SASP, resulting in enhanced expression of pro-inflammatory cytokines and adipokines, including leptin. Leptin is a noteworthy adipokine as its expression levels are not only associated with body fat content, but also with pain levels or pain sensitivity such as osteoarthritic pain or neuropathic pain. Systemic leptin is hence discussed as a biomarker for pain prediction in various pathologies and a first study published recently highlighted its potential application in predicting the duration of LBP.

Thirdly, atherosclerosis or high serum lipid levels may have a negative impact on IVD nutrition by impairing the diffusion of nutrients through the adjacent vertebrae into the IVD. Interestingly, high cholesterol not only leads to an accumulation of fat in endplates and vertebral bodies as recently described by Sasani et al., but also results in a higher prevalence of disc degeneration – likely due to nutritional deficits.

In summary, the biomechanical and biological consequences of obesity seem to contribute to IVD inflamma-ging (Figure 1). When taking into account that the prevalence of obesity has almost doubled over the past 30 years, this mechanism is likely to gain increasing importance in the years and decades to come.

A clinician’s perspective

Until today, clinicians are predominantly guided by the patient history, as well as by signs and symptoms in combination with neuroradiological imaging, especially magnetic resonance imaging (MRI). Neurosurgeons and orthopedic spine surgeons are trained with a mechanistic understanding of the prevalent pathologies. Therefore, mechanical approaches are usually offered to patients suffering from disc pathologies. This may include selective microsurgical removal of space occupying disc material, decompression of the spinal canal or in some cases fusion of the degenerated segment.

This review article shall help to increase the awareness that – aside from mechanical factors – local inflammation and specifically inflammaing play a crucial role in disc pathologies, including DDD. The pathological mechanisms may differ depending on the pro-inflammatory profile, likely reflected in the degree of pain experienced by patients. This has indeed a strong potential to change clinical practice from diagnosis to treatment.

Current efforts aim at combining technological developments with advancements in biology (including inflammation),
thereby building the foundation for improved diagnosis. This will not only be limited to improved MRI analysis, \(^{207}\) but may also entail tracing \(^{108}\) and assessment of biomarkers. \(^{109,110}\) Furthermore, a precise diagnosis will allow for more personalized treatments, for example through neutralization of specific cytokines. \(^{111}\) In the future, combination therapies that not only modulate inflammation, but also restore the ECM can be envisioned possibly by combining pharmaceuticals with, for example, stem cell application. \(^{112}\) Stem cells may not only counteract the degeneration-associated loss in ECM due to their anabolic function, but may also furthermore contribute to modulating inflammation via their anti-inflammatory and immune-modulatory capacity. \(^{113}\) Gene therapy or genome editing (such as CRISPR/Cas) could be used to mobilize the host cells and potentially provide long-lasting results. \(^{114,115}\)

This review clearly demonstrates that the mechanism of inflammaging is highly complex. Despite recent speculations on the role of \(P.\ acnes\) infection in inflammation and pain development in the IVD, biology-driven treatments cannot solely rely on the use of antibiotics to combat low-grade infection with \(P.\ acnes\) bacterium. Future research will be needed to better understand the interaction, crosstalk and association between the numerous cytokines involved in inflammaging and their role in the development of DDD and other disc pathologies. Increased knowledge will be crucial for the development of effective – and potentially personalized – molecular treatments targeting inflammaging.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Financial Support was obtained from the Swiss National Science Foundation (SNF PP00P2_163678/1) as well as from the Spine Society of Europe (Euros spine 2016_4).

**ORCID iD**

Aleksandra Sadowska [http://orcid.org/0000-0003-1344-7349](http://orcid.org/0000-0003-1344-7349)

Karin Wuertz-Kozak [http://orcid.org/0000-0002-3281-4629](http://orcid.org/0000-0002-3281-4629)

**References**

1. Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. *Mech Ageing Dev* 2007; 128: 92–105.

2. Castle SC. Clinical relevance of age-related immune dysfunction. *Clin Infect Dis* 2000; 31: 578–585.

3. Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. *Ann NY Acad Sci* 2000; 908: 244–254.

4. Xia SJ, Zhang XY, Zheng SB, et al. An update on inflamm-aging: mechanisms, prevention, and treatment. *J Immunol Res* 2016; 2016: 8426874.

5. Greene MA and Loeser RF. Aging-related inflammation in osteoarthritis. *Osteoarthritis Cartilage* 2015; 23: 1966–1971.

6. Morisette-Thomas V, Cohen AA, Fulop T, et al. Inflammaging does not simply reflect increases in pro-inflammatory markers. *Mech Ageing Dev* 2014; 139: 49–57.

7. Roberts S, Colombier P, Sowman A, et al. Ageing in the musculoskeletal system. *Acta Orthop* 2016; 87: 15–25.

8. Sadowska A, Touli E, Hitzl W, et al. Ageing in the spine: a systematic review. *Eur Spine J* 2015; 23: 1966–1971.

9. Luoma K, Riihimaki H, Luukkonen R, et al. Low back pain in relation to lumbar disc degeneration. *Spine (Phila Pa 1976)* 2000; 25: 487–492.

10. Balague F, Mannion AF, Pellise F, et al. Non-specific low back pain. *Lancet* 2012; 379: 482–491.

11. Colombini D, Occhipinti E, Alvarez-Casado E, et al. Manual lifting: a guide to the study of simple and complex lifting tasks. CRC Press, 2013, p.4.

12. Wieser S, Horisberger B, Schmidhauser S, et al. Cost of low back pain in Switzerland in 2005. *Eur J Health Econ* 2011; 12: 455–467.

13. Boos N, Weissbach S, Rohrbach H, et al. Classification of age-related changes in lumbar intervertebral discs. *Spine* 2002; 27: 2631–2644.

14. Gruber HE and Hanley EN. Analysis of aging and degeneration of the human intervertebral disc. Comparison of surgical specimens with normal controls. *Spine* 1998; 23: 751–757.

15. Iatridis JC, Godburn K, Wuertz K, et al. Region-dependent aggrecan degradation patterns in the rat intervertebral disc are affected by mechanical loading in vivo. *Spine* 2011; 36: 203–209.

16. Hasty P, Campisi J, Hoeijmakers J, et al. Aging and genome maintenance: lessons from the mouse? *Science* 2003; 299: 1355–1359.

17. Cheung KMC, Karppinen J, Chan D, et al. Prevalence and pattern of lumbar magnetic resonance imaging changes in a population study of one thousand forty-three individuals. *Spine* 2009; 34: 934–940.

18. Greenberg JO and Schnell RG. Magnetic resonance imaging of the lumbar spine in asymptomatic adults. Cooperative study–American Society of Neuroimaging. *J Neuroimaging* 1991; 1: 2–7.

19. Jensen MC, Brantzawadzki MN, Obuchowski N, et al. Magnetic-resonance-imaging of the lumbar spine in people without back pain. *New Engl J Med* 1994; 331: 69–73.

20. Ershler WB. Interleukin-6: a cytokine for gerontologists. *J Am Geriatr Soc* 1993; 41: 176–181.

21. Bruunsgaard H. Effects of tumor necrosis factor-alpha and interleukin-6 in elderly populations. *Eur Cytokine Netw* 2002; 13: 389–391.
22. Deng X, Zhao F, Kang B, et al. Elevated interleukin-6 expression levels are associated with intervertebral disc degeneration. *Exp Ther Med* 2016; 11: 1425–1432.
23. Weber KT, Alipui DO, Sison CP, et al. Serum levels of the proinflammatory cytokine interleukin-6 vary based on diagnoses in individuals with lumbar intervertebral disc diseases. *Arthritis Res Ther* 2016; 18: 3.
24. Schistad EI, Espeland A, Pedersen LM, et al. Association between baseline IL-6 and 1-year recovery in lumbar radicular pain. *Eur J Pain* 2014; 18: 1394–1401.
25. Pedersen LM, Schistad E, Jacobsen LM, et al. Serum levels of the pro-inflammatory interleukins 6 (IL-6) and 8 (IL-8) in patients with lumbar radicular pain due to disc herniation: a 12-month prospective study. *Brain Behav Immun* 2015; 46: 132–136.
26. Brisby H, Olmarker K, Larsson K, et al. Proinflammatory cytokines in cerebrospinal fluid and serum in patients with disc herniation and sciatica. *Eur Spine J* 2002; 11: 62–66.
27. Risbud MV and Shapiro IM. Role of cytokines in intervertebral disc degeneration: pain and disc content. *Nat Rev Rheumatol* 2014; 10: 44–56.
28. Wuertz K and Haglund L. Inflammatory mediators in intervertebral disc degeneration and discogenic pain. *Global Spine J* 2013; 3: 175–184.
29. Bachmeier BE, Nerlich AG, Weiler C, et al. Analysis of tissue distribution of TNF-alpha, TNF-alpha-receptors, and the activating TNF-alpha-convertase enzyme suggests activation of the TNF-alpha system in the aging intervertebral disc. *Am Ny Acad Sci* 2007; 1096: 44–54.
30. Wang C, Yu XH, Yan YG, et al. Tumor necrosis factor-alpha: a key contributor to intervertebral disc degeneration. *Acta Bioch Bioph Sin* 2017; 49: 1–13.
31. Le Maitre CL, Freemont AJ, Hoyland JA. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. *Arthritis Res Ther* 2005; 7: R732–R745.
32. Shamji MF, Setton LA, Jarvis W, et al. Proinflammatory cytokine expression profile in degenerated and herniated intervertebral disc tissues. *Arthritis Rheum-U*s 2010; 62: 1974–1982.
33. Lee S, Moon CS, Sul D, et al. Comparison of growth factor and cytokine expression in patients with degenerated disc disease and herniated nucleus pulposus. *Clin Biochem* 2009; 42: 1504–1511.
34. Purmessur D, Walter BA, Roughley PJ, et al. A role for TNF alpha in intervertebral disc degeneration: a non-recoverable catabolic shift. *Biochem Biophys Res Co* 2013; 433: 151–156.
35. Kang R, Li HS, Rickers K, et al. Intervertebral disc degenerative changes after intradiscal injection of TNF-alpha in a porcine model. *Eur Spine J* 2015; 24: 2010–2016.
36. Sutovsky J, Benco M, Sutovska M, et al. Cytokine and chemokine profile changes in patients with lower segment lumbar degenerative spondylolisthesis. *Int J Surg* 2017; 43: 163–170.
37. Cuellar JM, Golish SR, Reuter MW, et al. Cytokine evaluation in individuals with low back pain using discographic lavage. *Spine J* 2010; 10: 212–218.
38. Zhang Y, Chee A, Shi P, et al. Intervertebral disc cells produce interleukins found in patients with back pain. *Am J Phys Med Rehabil* 2016; 95: 407–415.
39. Kepler CK, Markova DZ, Dibra F, et al. Expression and relationship of proinflammatory chemokine RANTES/CCL5 and cytokine IL-1beta in painful human intervertebral discs. *Spine (Phila Pa 1976)* 2013; 38: 873–880.
40. Navone SE, Marfia G, Giannoni A, et al. Inflammatory mediators and signalling pathways controlling intervertebral disc degeneration. *Histol Histopathol* 2017; 32: 523–542.
41. Johnson ZI, Schoepflin ZR, Choi H, et al. Disc in flames: roles of TNF-alpha and IL-1beta in intervertebral disc degeneration. *Eur Cell Mater* 2015; 30: 104–116; discussion 16–7.
42. Kim KW, Chung HN, Ha KY, et al. Senescence mechanisms of nucleus pulposus chondrocytes in human intervertebral discs. *Spine J* 2009; 9: 658–666.
43. Roberts S, Evans EH, Kletsas D, et al. Senescence in human intervertebral discs. *Eur Spine J* 2006; 15: S312–S316.
44. Le Maitre CL, Freemont AJ and Hoyland JA. Accelerated cellular senescence in degenerate intervertebral discs: a possible role in the pathogenesis of intervertebral disc degeneration. *Arthritis Res Ther* 2007; 9(3): R45.
45. Gruber HE, Ingram JA, Norton HJ, et al. Senescence in cells of the aging and degenerating intervertebral disc: immunocalization of senescence-associated beta-galactosidase in human and sand rat discs. *Spine* 2007; 32: 321–327.
46. Dimozi A, Mavrogonatou E, Skliarou A, et al. Oxidative stress inhibits the proliferation, induces premature senescence and promotes a catabolic phenotype in human nucleus pulposus intervertebral disc cells. *Eur Cell Mater* 2015; 30: 89–102; discussion 3.
47. Jeong SW, Lee JS and Kim KW. In vitro lifespan and senescence mechanisms of human nucleus pulposus chondrocytes. *Spine J* 2014; 14: 499–504.
48. Vamvakas SS, Mavrogonatou E and Kletsas D. Human nucleus pulposus intervertebral disc cells becoming senescent using different treatments exhibit a similar transcriptional profile of catabolic and inflammatory genes. *Eur Spine J* 2017; 26: 2063–2071.
49. Vo NV, Hartman RA, Patil PR, et al. Molecular mechanisms of biological aging in intervertebral discs. *J Orthop Res* 2016; 34: 1289–1306.
50. Chan SCW, Walser J, Kappeli P, et al. Region specific response of intervertebral disc cells to complex dynamic loading: an organ culture study using a dynamic torsion-compression bioreactor. *Plos One* 2013; 8(8): e72489.
51. Setton LA and Chen J. Mechanobiology of the intervertebral disc and relevance to disc degeneration. *J Bone Joint Surg Am* 2006; 88a: 52–7.
52. Neidlinger-Wilke C, Wurz K, Urban JPG, et al. Regulation of gene expression in intervertebral disc cells by low and high hydrostatic pressure. *Eur Spine J* 2006; 15: S372–S378.
53. Sowa GA, Coelho JP, Bell KM, et al. Alterations in gene expression in response to compression of nucleus pulposus cells. *Spine J* 2011; 11: 36–43.
54. Gilbert HTJ, Hoyland JA, Freemont AJ, et al. The involvement of interleukin-1 and interleukin-4 in the response of human annulus fibrosus cells to cyclic tensile strain: an altered mechanotransduction pathway with degeneration. *Arthritis Res Ther* 2011; 13(1): R8.

55. Gilbert HTJ, Hoyland JA and Millward-Sadler SJ. The response of human annulus fibrosus cells to cyclic tensile strain is frequency-dependent and altered with disc degeneration. *Arthritis Rheum-Us* 2010; 62: 3385–3394.

56. Gawri R, Rosenzweig DH, Krock E, et al. High mechanical strain of primary intervertebral disc cells promotes secretion of inflammatory factors associated with disc degeneration and pain. *Arthritis Res Ther* 2014; 16(1): R21.

57. Walter BA, Korecki CL, Purmessur D, et al. Complex loading affects intervertebral disc mechanics and biology. *Osteoarthr Cartilage* 2011; 19: 1011–1018.

58. Miyagi M, Ishikawa T, Kamoda H, et al. ISSLS prize winner: disc dynamic compression in rats produces long-lasting increases in inflammatory mediators in discs and induces long-lasting nerve injury and regeneration of the afferent fibers innervating discs a pathomechanism for chronic disogenic low back pain. *Spine* 2012; 37: 1810–1818.

59. O’Connell GD, Vresilovic EJ and Elliott DM. Human intervertebral disc internal strain in compression: the effect of disc region, loading position, and degeneration. *J Orthop Res* 2011; 29: 547–555.

60. Walter BA, Purmessur D, Moon A, et al. Reduced tissue osmolarity increases TRPV4 expression and pro-inflammatory cytokines in intervertebral disc cells. *Eur Cell Mater* 2016; 32: 123–136.

61. Krupkova O, Zvick J and Elliott DM. Human intervertebral disc internal strain in compression: the effect of disc region, loading position, and degeneration. *J Orthop Res* 2011; 29: 547–555.

62. Urban JP and Roberts S. Degeneration of the intervertebral disc. *Arthritis Res Ther* 2003; 5: 120–130.

63. Singh K, Masuda K, Thonar EJ, et al. Age-related changes in the extracellular matrix of nucleus pulposus and anulus fibrosus of human intervertebral disc. *Spine (Phila Pa 1976)* 2009; 34: 10–16.

64. Quero L, Klawitter M, Schmaus A, et al. Hyaluronic acid fragments enhance the inflammatory and catabolic response in human intervertebral disc cells through modulation of toll-like receptor-2 signalling pathways. *Arthritis Res Ther* 2013; 15: R94.

65. Brown S, Melrose J, Caterson B, et al. A comparative evaluation of the small leucine-rich proteoglycans of pathological human intervertebral discs. *Eur Spine J* 2012; 21(Suppl 2): S154–S159.

66. Schaefer L, Babelova A, Kiss E, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptor-4 and-2 in macrophages. *N-S Arch Pharmacol* 2006; 372: 21.

67. Moreth K, Iozzo RV and Schaefer L. Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation. *Cell Cycle* 2012; 11: 2084–2091.

68. Ruel N, Markova DZ, Adams SL, et al. Fibronectin fragments and the cleaving enzyme ADAM-8 in the degenerative human intervertebral disc. *Spine* 2014; 39: 1274–1279.

69. Anderson DG, Markova D, Adams SL, et al. Fibronectin splicing variants in human intervertebral disc and association with disc degeneration. *Spine* 2010; 35: 1581–1588.

70. Arroyo AG and Iruela-Arispe ML. Extracellular matrix, inflammation, and the angiogenic response. *Cardiovasc Res* 2010; 86: 226–235.

71. Adair-Kirk TL and Senior RM. Fragments of extracellular matrix as mediators of inflammation. *Int J Biochem Cell B* 2008; 40: 1101–1110.

72. Almine JF, Wise SG, Hiob M, et al. Elastin sequences trigger transient proinflammatory responses by human dermal fibroblasts. *Faseb J* 2013; 27: 3455–3465.

73. Albert HB, Lambert P, Rollason J, et al. Does nuclear tissue infected with bacteria following disc herniations lead to Modic changes in the adjacent vertebrae? *Eur Spine J* 2013; 22: 690–696.

74. Albert HB, Kjaer P, Jensen TS, et al. Modic changes, possible causes and relation to low back pain. *Med Hypotheses* 2008; 70: 361–368.

75. McLorinan GC, Glenn JV, McMullan MG, et al. *Propionibacterium acnes* wound contamination at the time of spinal surgery. *Clin Orthop Relat Res* 2005; 437: 67–73.

76. Zhou ZZ, Chen Z, Zheng YH, et al. Relationship between annular tear and presence of Propionibacterium acnes in lumbar intervertebral disc. *Eur Spine J* 2015; 24: 2496–2502.

77. Capoor MN, Ruzicka F, Schmitz JE, et al. *Propionibacterium acnes* biofilm is present in intervertebral discs of patients undergoing microdiscectomy. *Plos One* 2017; 12(4): e0174518.

78. Dudi S, Miller S, Demir-Deviren S, et al. Inflammatory response of disc cells against Propionibacterium acnes depends on the presence of lumbar Modic changes. *Eur Spine J* 2017; 1–8. Available at: https://doi.org/10.1007/s00586-017-5291-4.

79. Arndt J, Charles YP, Koebel C, et al. Bacteriology of degenerated lumbar intervertebral disks. *J Spinal Disord Tech* 2012; 25: E211–E216.

80. Yuan Y, Chen Y, Zhou Z, et al. Association between chronic inflammation and latent infection of Propionibacterium acnes in non-pyogenic degenerated intervertebral discs: a pilot study. *Eur Spine J* 2017; 1–12. Available at: https://doi.org/10.1007/s00586-017-5363-5.

81. Lwin SM, Kimber I and McFadden JP. Acne, quorum sensing and danger. *Clin Exp Dermatol* 2014; 39: 162–167.

82. Guh DP, Zhang W, Bansback N, et al. The incidence of comorbidities related to obesity and overweight: a systematic review and meta-analysis. *Bmc Public Health* 2009; 9: 88.

83. Schelbert KB. Comorbidities of obesity. *Primary Care* 2009; 36: 271–.

84. Jakoi AM, Pannu G, D’Oro A, et al. The clinical correlations between diabetes, cigarette smoking and obesity on intervertebral degenerative disc disease of the lumbar spine. *Asian Spine J* 2017; 11: 337–347.
85. Shiri R, Karppinen J, Leino-Arjas P, et al. The association between obesity and low back pain: a meta-analysis. Am J Epidemiol 2010; 171: 135–154.
86. Dario AB, Ferreira ML, Refshauge KM, et al. The relationship between obesity, low back pain, and lumbar disc degeneration when genetics and the environment are considered: a systematic review of twin studies. Spine J 2015; 15: 1106–1117.
87. Mellissas J, Volakakis E and Hadjipavlou A. Low-back pain in morbidly obese patients and the effect of weight loss following surgery. Obes Surg 2003; 13: 389–393.
88. Urquhart DM, Kurniadi I, Triangto K, et al. Obesity is associated with reduced disc height in the lumbar spine but not at the lumbosacral junction. Spine 2014; 39: E962–E966.
89. Liuke M, Solovieva S, Lamminen A, et al. Disc degeneration of the lumbar spine in relation to overweight. Int J Obesity 2005; 29: 903–908.
90. Samartzis D, Karppinen J, Chan D, et al. The association of lumbar intervertebral disc degeneration on magnetic resonance imaging with body mass index in overweight and obese adults: a population-based study. Arthritis Rheum US 2012; 64: 1488–1496.
91. Kirkland J, Tchkonia T, Pirtskhalava T, et al. Aging, fat tissue, inflammation, and cellular senescence. Gerontology 2012; 52: 492.
92. Tchkonia T, MORbeck DE, von Zglinicki T, et al. Fat tissue, aging, and cellular senescence. Aging Cell 2010; 9: 667–684.
93. Samartzis D, Karppinen J, Cheung JP, et al. Disk degeneration and low back pain: are they fat-related conditions? Global Spine J 2013; 3: 133–144.
94. Ahima RS. Revisiting leptin’s role in obesity and weight loss. J Clin Invest 2008; 118: 2380–2383.
95. Younger J, Kapphahn K, Brennan K, et al. Association of leptin with body pain in women. J Womens Health (Larchmt) 2016; 25: 752–760.
96. Gandhi R, Takahashi M, Smith H, et al. The synovial fluid adiponectin-leptin ratio predicts pain with knee osteoarthritis. Clin Rheumatol 2010; 29: 1223–1228.
97. Lim G, Wang S, Zhang Y, et al. Spinal leptin contributes to the pathogenesis of neuropathic pain in rodents. J Clin Invest 2009; 119: 295–304.
98. Lubeke A, Finckh A, Puskas GJ, et al. Do synovial leptin levels correlate with pain in end stage arthritis? Int Orthop 2013; 37: 2071–2079.
99. Galletti F, Barbato A, Versiero M, et al. Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: an 8-year follow-up study. J Hypertens 2007; 25: 1671–1677.
100. Osorio CF, de Souza DB, Gallo CBM, et al. Leptin and leptin receptor expressions in prostate tumors may predict disease aggressiveness? Acta Cir Bras 2014; 29: 44–48.
101. Lippi G, Dagnostino C, Buonocore R, et al. The serum concentrations of leptin and MCP-1 independently predict low back pain duration. Clin Chem Lab Med 2017; 55: 1368–1374.
102. Kauppila LI. Atherosclerosis and disc degeneration/low-back pain–a systematic review. Eur J Vasc Endovasc 2009; 37: 661–670.
103. Sasani M, Aydin AL, Aytan N, et al. Effect of a hypercholesterolemia as a starting factor on spinal degeneration in rabbits and role of vitamin E (alpha-tocopherol). Surg Neurol Int 2016; 7: 36.
104. Urban JP, Smith S and Fairbank JCT. Nutrition of the intervertebral disc. Spine 2004; 29: 2700–2709.
105. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557–567.
106. Leung YY, Huebner JL, Haaland B, et al. Synovial fluid pro-inflammatory profile differs according to the characteristics of knee pain. Osteoarthritis Cartilage 2017; 25: 1420–1427.
107. Waldenberg C, Helbelka H, Brisby H, et al. MRI histogram analysis enables objective and continuous classification of intervertebral disc degeneration. Eur Spine J 2017, 1–7. https://doi.org/10.1007/s00586-017-5264-7.
108. Xiao L, Ding M, Zhang Y, et al. A novel modality for functional imaging in acute intervertebral disk herniation via tracking leukocyte infiltration. Mol Imaging Biol 2017; 19: 703–713.
109. Haneder S, Apprich SR, Schmitt B, et al. Assessment of glycosaminoglycan content in intervertebral discs using chemical exchange saturation transfer at 3.0 Tesla: preliminary results in patients with low-back pain. Eur Radiol 2013; 23: 861–868.
110. Kandahari AM, Yang X, Dighe AS, et al. Recognition of immune response for the early diagnosis and treatment of osteoarthritis. J Immunol Res 2015; 2015: 192415.
111. Rider P, Carmi Y and Cohen I. Biologics for targeting inflammatory cytokines, clinical uses, and limitations. Int J Cell Biol 2016; 2016: 9259646.
112. Sakai D. Future perspectives of cell-based therapy for intervertebral disc disease. Eur Spine J 2008; 17(Suppl 4): 452–458.
113. Kroek E, Rosenzweig DH and Haglund L. The inflammatory milieu of the degenerate disc: is mesenchymal stem cell-based therapy for intervertebral disc repair a feasible approach? Curr Stem Cell Res Ther 2015; 10: 317–328.
114. Nishida K, Suzuki T, Kakutani K, et al. Gene therapy approach for disc degeneration and associated spinal disorders. Eur Spine J 2008; 17(Suppl 4): 459–466.
115. Farhang N, Brunger JM, Stover JD, et al. *CRISPR-based epigenome editing of cytokine receptors for the promotion of cell survival and tissue deposition in inflammatory environments. Tissue Eng Part A 2017; 23: 738–749.